34只权益基金年内业绩翻倍，基金经理三季报已提示“AI太贵”

Group 1 - The overall valuation of the AI sector is no longer at a low level after significant increases, with some popular stocks reflecting optimistic growth expectations for the coming years [1][4] - As of October 27, the Shanghai Composite Index reached a ten-year high of 3999.07 points, with year-to-date increases of 19.25% for the Shanghai Index, 29.52% for the Shenzhen Component Index, and 51.03% for the ChiNext Index [1] - A significant number of equity funds have seen returns exceeding 100% this year, with notable funds like Yongying Technology Smart A achieving a return of 206.10% [2][3] Group 2 - The strong performance of equity funds is attributed to investments in high-tech and information technology sectors, with top holdings in funds like Yongying Technology Smart A being leaders in the optical packaging sector [3] - The CPO index has increased by over 100% this year, indicating strong market performance in this segment [3] - Fund managers are advising investors to diversify their investments to mitigate risks associated with high volatility in tool-based products [3][4] Group 3 - Despite the overall positive performance of equity funds, some funds, particularly in the healthcare sector, have reported losses, with certain funds down over 10% year-to-date [5] - The healthcare sector experienced a significant rise earlier in the year, with the China Medical Index increasing nearly 30% from April to early September, followed by a decline due to various factors [5] - Some healthcare funds have adjusted their portfolios to include a more balanced structure across different segments, indicating a shift towards a more rational investment approach [5] Group 4 - The public fund industry has increased its research activities during the earnings report season, with a notable focus on the pharmaceutical and biotechnology sectors, which received the highest number of inquiries [6][7] - A total of 140 public fund institutions conducted 1188 research sessions on A-share listed companies, with the pharmaceutical sector being the most scrutinized [6] - The increased frequency of research is aimed at validating company performance and assessing the sustainability of growth, which is crucial for investment decisions [7]